#United States #New York #Gross Law Firm #Regeneron Pharmaceuticals #Eylea

Urgent Notice for Regeneron Pharmaceuticals, Inc. Shareholders

Shareholders who have incurred losses from their investments in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) are being prompted to consider participation in a pending class action lawsuit. This action is spearheaded by The Gross Law Firm, which represents affected investors in seeking restitution for alleged fraudulent practices associated with the company.

Background of the Case

The proposed class action revolves around allegations that from November 2, 2023, to October 30, 2024, Regeneron misrepresented significant facts regarding its business operations and financial practices related to its leading product, Eylea. The lawsuit claims that the company's conduct artificially inflated the sales figures of Eylea, making it misleading to investors regarding the health and future prospects of the company.

Allegations Against Regeneron

1. Misleading Statements: It is alleged that Regeneron issued false statements related to its pricing and sales practices, particularly concerning its dealings with distributors regarding credit card transaction fees.
2. Price Subsidization: The complaint asserts that Regeneron was subsidizing prices for customers purchasing Eylea with credit cards, falsely boosting reported sales figures and consequently leading to a misleading outlook on profitability.
3. Competitive Advantage Through Misrepresentation: The company allegedly gained an unfair competitive muscle by not disclosing significant price concessions related to the credit card fees, which allowed it to misrepresent its standing in the market.
4. Financial Outcome Misrepresentation: These actions resulted in an overstated average selling price reported to federal agencies, violating the False Claims Act and misleading shareholders regarding the company’s earnings.

Important Deadlines

Shareholders are reminded that the deadline for registering to potentially become a lead plaintiff in this case is set for March 10, 2025. It is crucial for affected parties to act promptly to ensure they have the opportunity to recover any losses incurred during the class period. Interested individuals can initiate their registration by visiting the provided link in this notice.

Next Steps for Investors

Upon registration, participants will benefit from portfolio monitoring services offered by The Gross Law Firm, ensuring timely updates regarding the litigation process. Registration incurs no costs and places no commitments on shareholders but stands as a vital step towards pursuing compensation for losses suffered due to alleged misleading actions by Regeneron.

Why Choose The Gross Law Firm?

The Gross Law Firm is a well-respected class action firm dedicated to protecting the rights of investors. With a focus on holding companies accountable for false representations and deceptive practices, the firm aims to recover damages for investors impacted by misconduct. Their team is committed to transparent communication and will work towards ensuring all participants are informed about their legal standing and any developments in the class action.

Contact Information

Individuals interested in joining the lawsuit or seeking further assistance can reach out to The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: info@grosslawfirm.com
• - Phone: (646) 453-8903

Investors are encouraged to take immediate action to safeguard their financial interests. By participating in this class action lawsuit, shareholders can assert their rights against corporate malfeasance and work towards obtaining the compensation they rightfully deserve.